Compare VFF & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFF | ENTA |
|---|---|---|
| Founded | 1989 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.1M | 407.5M |
| IPO Year | N/A | 2013 |
| Metric | VFF | ENTA |
|---|---|---|
| Price | $3.62 | $14.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $20.33 |
| AVG Volume (30 Days) | ★ 3.0M | 298.3K |
| Earning Date | 11-10-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $351,979,000.00 | $65,324,000.00 |
| Revenue This Year | N/A | $2.13 |
| Revenue Next Year | $6.00 | $2.74 |
| P/E Ratio | $18.97 | ★ N/A |
| Revenue Growth | ★ 56.61 | N/A |
| 52 Week Low | $0.45 | $4.09 |
| 52 Week High | $4.08 | $15.34 |
| Indicator | VFF | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 51.56 | 72.29 |
| Support Level | $3.58 | $11.89 |
| Resistance Level | $4.04 | $14.51 |
| Average True Range (ATR) | 0.30 | 0.85 |
| MACD | -0.02 | 0.13 |
| Stochastic Oscillator | 39.29 | 89.18 |
Village Farms International Inc owns and operates intensive agricultural greenhouse facilities in British Columbia and Texas, where it produces, markets and sells tomatoes, bell peppers and cucumbers. Its wholly owned subsidiary, Pure Sunfarms, is a vertically integrated licensed producer and supplier of cannabis products sold to other licensed providers and provincial governments across Canada and internationally. The Company's wholly owned subsidiary, Balanced Health, develops and sells, cannabidiol (CBD) based products including ingestible, edible and topical applications. The operating segments of the Company are VF Fresh (Produce), Cannabis Canada, Cannabis U.S., Clean Energy, and Leli . The company makes majority of its revenue from the Produce segment.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.